Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

CBL & Associates Properties is a strong Buy as AFFO growth, stock buybacks, and rate cuts drive value in the retail REIT ...

Nuvama has reiterated its 'Buy' recommendation for RIL shares, emphasising the potential growth in the NE sector, which could ...